サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298441

胃がん市場：疾患タイプ別、治療タイプ別、薬剤クラス展望別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2021-2031年

Gastric Cancer Market By Disease Type, By Treatment Type, By Drug Class Outlook, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 350 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
胃がん市場：疾患タイプ別、治療タイプ別、薬剤クラス展望別、投与経路別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年04月01日
発行: Allied Market Research
ページ情報: 英文 350 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の胃がん市場は、2022年から2031年までのCAGR17.9%で、2021年の21億米ドルから成長し、2031年には107億米ドルに達すると予測されます。

Gastric Cancer Market-IMG1

胃がんは、胃の粘膜に悪性（がん）細胞ができる病気です。年齢、食生活、座りがちな生活習慣などが胃がん発症のリスクにつながります。胃がんの症状には、消化不良や胃の不快感や痛みなどがあります。胃がんの診断には、胃や食道を調べる検査が用いられます。

胃がん患者は増加傾向にあり、胃がん市場は拡大が見込まれます。胃がんの原因は、肥満の増加、高度に加工された食品、甘い飲料の摂取の増加、喫煙、遺伝子の遺伝子組み換え、がんの家族歴、アルコールの摂取などの付加的な危険因子により著しく増加しています。さらに、胃がんの罹患率の上昇は今後も続くと予想され、この動向が効率的な治療法の需要を押し上げています。これらすべての要因が、予測期間中の市場収益成長を促進すると予測されます。

胃がん治療は、手術、放射線療法、診断、病期分類など、実施しなければならない検査が数多くあるため、高額になる可能性があります。胃がんの診断や病期分類には、画像検査、内視鏡検査、生検、血液検査など、さまざまな検査や処置が頻繁に必要となります。これらの検査には高額な費用がかかり、複数回の受診が必要になることもあります。胃がんの治療費は高額であるため、市場は大きな制約を受けると予測されます。

胃がん市場は、ヘルスケアに対する意識の高まりにより恩恵を受けると予測されます。胃がんに関連する危険因子に対する認識が高まるにつれて、医療機関を受診したり検診を受けたりする傾向が強まる。胃がんに対する認識が高まることで、より多くの症例がより早い段階で発見されるようになります。胃がんの早期発見は、効果的な治療と患者の予後改善に不可欠です。したがって、胃がん患者は薬物療法、手術療法、放射線療法などの診断・治療オプションを必要とする可能性があります。これらの要因は、市場で事業を展開する大手企業にとって、いくつかの成長機会を生み出すと期待されています。

COVID-19の大流行は、胃がんの治療、特にスクリーニング、診断、治療のタイミングに悪影響を及ぼしました。COVID-19は、ほとんどすべての産業に影響を及ぼした前例のない世界の公衆衛生上の緊急事態であり、その長期的な影響は、大流行後の期間にさまざまな最終用途産業の成長に反映されると予測されています。多くの胃がん患者がパンデミックによる治療の中断を経験しています。COVID-19感染のリスクを減らすために、治療スケジュールを変更しなければならず、その結果、一部の患者の治療計画が遅れたり変更されたりしました。ヘルスケア環境でのCOVID-19曝露に対する懸念から、患者は治療を受けることをためらっています。胃がんの臨床試験はパンデミックの影響を大きく受け、多くの臨床試験が延期または遅延しました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19：市場への影響分析
  • 平均販売価格
  • ブランドシェア分析
  • 主要規制分析
  • 市場シェア分析
  • 特許情勢
  • 規制ガイドライン
  • バリューチェーン分析

第4章 胃がん市場：疾患タイプ別

  • 概要
    • 市場規模および予測
  • 腺がん
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • リンパ腫
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 消化管間質腫瘍
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • カルチノイド腫瘍
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 胃がん市場：治療タイプ別

  • 概要
    • 市場規模および予測
  • 免疫療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 標的療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 化学療法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 放射線療法・手術
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 胃がん市場：薬剤クラス展望別

  • 概要
    • 市場規模および予測
  • PD-1/PD-L1阻害薬
    • 主な市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場シェア分析：国別
  • HER2拮抗薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • VEGFR2拮抗薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 胃がん市場：投与経路別

  • 概要
    • 市場規模および予測
  • 経口
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 注射剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第8章 胃がん市場：流通チャネル別

  • 概要
    • 市場規模および予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 専門薬局と小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第9章 胃がん市場：地域別

  • 概要
    • 市場規模・予測： 地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：薬剤クラス展望別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：薬剤クラス展望別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：薬剤クラス展望別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 中国
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 日本
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 韓国市場
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：薬剤クラス展望別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • アラブ首長国連邦
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 南アフリカ
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他の地域
      • 主な市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：薬剤クラス展望別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別

第10章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第11章 企業プロファイル

  • Novartis AG
  • Pfizer, Inc.
  • Mylan N.V.
  • F. Hoffmann La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.
  • samsung bioepis
  • Bristol Myers Squibb Company
図表

LIST OF TABLES

  • TABLE 01. GLOBAL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 02. GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. GASTRIC CANCER MARKET FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 08. GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. GLOBAL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 13. GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. GLOBAL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 18. GASTRIC CANCER MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. GASTRIC CANCER MARKET FOR INJECTABLE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 21. GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. GASTRIC CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. GASTRIC CANCER MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. U.S. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 32. U.S. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 33. U.S. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 34. U.S. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. U.S. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. CANADA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 37. CANADA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 38. CANADA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 39. CANADA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 40. CANADA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 44. MEXICO GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 45. MEXICO GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 50. EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. EUROPE GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. GERMANY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 53. GERMANY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 54. GERMANY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 55. GERMANY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 56. GERMANY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. UK GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. UK GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 59. UK GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 60. UK GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 61. UK GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. FRANCE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. FRANCE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 64. FRANCE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 65. FRANCE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 66. FRANCE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. SPAIN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 68. SPAIN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 69. SPAIN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 70. SPAIN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 71. SPAIN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. ITALY GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 73. ITALY GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 74. ITALY GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 75. ITALY GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 76. ITALY GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. REST OF EUROPE GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 78. REST OF EUROPE GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 80. REST OF EUROPE GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. REST OF EUROPE GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 86. ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. ASIA-PACIFIC GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 88. CHINA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 89. CHINA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 90. CHINA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 91. CHINA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 92. CHINA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 93. JAPAN GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 94. JAPAN GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 95. JAPAN GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 96. JAPAN GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 97. JAPAN GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 98. INDIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 99. INDIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 100. INDIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 101. INDIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 102. INDIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH KOREA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 104. SOUTH KOREA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 105. SOUTH KOREA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 106. SOUTH KOREA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 107. SOUTH KOREA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 108. AUSTRALIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 109. AUSTRALIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 110. AUSTRALIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 111. AUSTRALIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 112. AUSTRALIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 113. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 114. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 116. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 118. LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 119. LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 120. LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 121. LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 122. LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 123. LAMEA GASTRIC CANCER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 124. BRAZIL GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 125. BRAZIL GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 126. BRAZIL GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 127. BRAZIL GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 128. BRAZIL GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 129. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 130. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 131. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 132. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 133. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 134. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 135. SAUDI ARABIA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 136. SAUDI ARABIA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 137. SAUDI ARABIA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 138. SAUDI ARABIA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 139. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 140. SOUTH AFRICA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 141. SOUTH AFRICA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 142. SOUTH AFRICA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 143. SOUTH AFRICA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 144. REST OF LAMEA GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 145. REST OF LAMEA GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021-2031 ($MILLION)
  • TABLE 146. REST OF LAMEA GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021-2031 ($MILLION)
  • TABLE 147. REST OF LAMEA GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 148. REST OF LAMEA GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 149. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 150. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 151. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 152. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 153. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 154. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 155. F. HOFFMANN LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 156. F. HOFFMANN LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 157. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 158. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 159. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 160. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 161. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 162. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 163. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES
  • TABLE 164. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT
  • TABLE 165. SAMSUNG BIOEPIS: KEY EXECUTIVES
  • TABLE 166. SAMSUNG BIOEPIS: COMPANY SNAPSHOT
  • TABLE 167. BRISTOL MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 168. BRISTOL MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. GASTRIC CANCER MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF GASTRIC CANCER MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN GASTRIC CANCER MARKET (2022-2031)
  • FIGURE 04. PORTER FIVE-1
  • FIGURE 05. PORTER FIVE-2
  • FIGURE 06. PORTER FIVE-3
  • FIGURE 07. PORTER FIVE-4
  • FIGURE 08. PORTER FIVE-5
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALGASTRIC CANCER MARKET
  • FIGURE 10. IMPACT OF KEY REGULATION: GASTRIC CANCER MARKET
  • FIGURE 11. MARKET SHARE ANALYSIS: GASTRIC CANCER MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES: GASTRIC CANCER MARKET
  • FIGURE 15. VALUE CHAIN ANALYSIS: GASTRIC CANCER MARKET
  • FIGURE 16. GASTRIC CANCER MARKET, BY DISEASE TYPE, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR ADENOCARCINOMA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR LYMPHOMA, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR GASTROINTESTINAL STROMAL TUMOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR CARCINOID TUMOR, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 22. GASTRIC CANCER MARKET, BY TREATMENT TYPE, 2021(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR RADIATION THERAPY AND SURGERY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 27. GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK, 2021(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR PD-1/PD-L1 INHIBITORS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR HER2 ANTAGONISTS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR VEGFR2 ANTAGONISTS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 31. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 32. GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 33. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR ORAL, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 34. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR INJECTABLE, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 35. GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 36. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 37. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR SPECIALTY AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 38. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 39. GASTRIC CANCER MARKET BY REGION, 2021
  • FIGURE 40. U.S. GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. CANADA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. MEXICO GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. GERMANY GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. UK GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. FRANCE GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. SPAIN GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. ITALY GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. REST OF EUROPE GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. CHINA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 50. JAPAN GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 51. INDIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 52. SOUTH KOREA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 53. AUSTRALIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 54. REST OF ASIA-PACIFIC GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 55. BRAZIL GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 56. UNITED ARAB EMIRATES GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 57. SAUDI ARABIA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 58. SOUTH AFRICA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 59. REST OF LAMEA GASTRIC CANCER MARKET, 2021-2031 ($MILLION)
  • FIGURE 60. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 61. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 62. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 63. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 64. COMPETITIVE DASHBOARD
  • FIGURE 65. COMPETITIVE HEATMAP: GASTRIC CANCER MARKET
  • FIGURE 66. TOP PLAYER POSITIONING, 2021
目次
Product Code: A74458

The global gastric cancer market is anticipated to reach $10.7 billion by 2031, growing from $2.1 billion in 2021, at a CAGR of 17.9% from 2022 to 2031.

Gastric Cancer Market - IMG1

Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Age, diet, and sedentary lifestyle can lead to the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. Tests that examine the stomach and esophagus are used to diagnose gastric cancer.

The gastric cancer market is expected to expand as cases of the stomach disease rise. The causes of stomach cancer have significantly increased due to additional risk factors such as an increase in obesity, increase in the consumption of highly processed foods, sugary beverages, smoking, genetic modification of genes, a family history of cancer, and consumption of alcohol. Furthermore, the rising incidence of gastric cancer is anticipated to continue and this trend is boosting the demand for efficient treatments. All these factors are projected to drive the market revenue growth during the forecast period.

Gastric cancer treatment can be expensive as there are numerous tests which need to be conducted, including surgery, radiation therapy, and diagnosis, and staging. Different tests and procedures, such as imaging studies, endoscopies, biopsies, and blood tests, are frequently required in the diagnosis and staging of gastric cancer. The cost of these tests can be high, and multiple doctor visits might be necessary. The market is predicted to be severely constrained by the high cost of treating gastric cancer.

The market for gastric cancer is projected to benefit due to the increase in healthcare awareness. People are more likely to seek medical attention and get screened for the disease as they become more aware of the risk factors linked to gastric cancer. More cases of gastric cancer can be discovered at an earlier stage owing to the increase in awareness. Early detection of gastric cancer is essential for effective treatment and better patient outcomes. Therefore, gastric cancer patient may need diagnostic and therapeutic options like medication, surgery, and radiation therapy. These factors are expected to create several growth opportunities for the major players operating in the market.

The COVID-19 pandemic had a detrimental effect on the treatment of gastric cancer, especially in terms of the timing of screening, diagnosis, and treatment.COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the post-pandemic period. Many gastric cancer patients have experienced treatment interruptions due to the pandemic. To reduce the risk of COVID-19 transmission, treatment schedules had to be altered, which resulted in delays or changes to some patients' treatment plans. Concerns about COVID-19 exposure in healthcare settings made patients hesitant to seek treatment. Clinical trials for gastric cancer were significantly impacted by the pandemic as numerous clinical trials were postponed or delayed.

The key players profiled in this report include: Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastric cancer market analysis from 2021 to 2031 to identify the prevailing gastric cancer market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gastric cancer market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gastric cancer market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal Stromal Tumor
  • Carcinoid Tumor
  • Others

By Treatment Type

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy and Surgery

By Drug Class Outlook

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Specialty and Retail Pharmacies
  • Others
  • Hospital Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Pfizer, Inc.
    • Mylan N.V.
    • F. Hoffmann La Roche Ltd.
    • Eli Lilly And Company
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • samsung bioepis
    • Bristol Myers Squibb Company

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. COVID-19 Impact Analysis on the market
  • 3.6. Average Selling Price
  • 3.7. Brand Share Analysis
  • 3.8. Key Regulation Analysis
  • 3.9. Market Share Analysis
  • 3.10. Patent Landscape
  • 3.11. Regulatory Guidelines
  • 3.12. Value Chain Analysis

CHAPTER 4: GASTRIC CANCER MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Adenocarcinoma
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Lymphoma
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Gastrointestinal Stromal Tumor
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Carcinoid Tumor
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: GASTRIC CANCER MARKET, BY TREATMENT TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Immunotherapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Targeted Therapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Chemotherapy
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Radiation Therapy and Surgery
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: GASTRIC CANCER MARKET, BY DRUG CLASS OUTLOOK

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. PD-1/PD-L1 Inhibitors
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. HER2 Antagonists
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. VEGFR2 Antagonists
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: GASTRIC CANCER MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Oral
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Injectable
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: GASTRIC CANCER MARKET, BY DISTRIBUTION CHANNEL

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. Hospital Pharmacies
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by region
    • 8.2.3. Market share analysis by country
  • 8.3. Specialty and Retail Pharmacies
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by region
    • 8.3.3. Market share analysis by country
  • 8.4. Others
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by region
    • 8.4.3. Market share analysis by country

CHAPTER 9: GASTRIC CANCER MARKET, BY REGION

  • 9.1. Overview
    • 9.1.1. Market size and forecast By Region
  • 9.2. North America
    • 9.2.1. Key trends and opportunities
    • 9.2.2. Market size and forecast, by Disease Type
    • 9.2.3. Market size and forecast, by Treatment Type
    • 9.2.4. Market size and forecast, by Drug Class Outlook
    • 9.2.5. Market size and forecast, by Route of Administration
    • 9.2.6. Market size and forecast, by Distribution Channel
    • 9.2.7. Market size and forecast, by country
      • 9.2.7.1. U.S.
      • 9.2.7.1.1. Key market trends, growth factors and opportunities
      • 9.2.7.1.2. Market size and forecast, by Disease Type
      • 9.2.7.1.3. Market size and forecast, by Treatment Type
      • 9.2.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.1.5. Market size and forecast, by Route of Administration
      • 9.2.7.1.6. Market size and forecast, by Distribution Channel
      • 9.2.7.2. Canada
      • 9.2.7.2.1. Key market trends, growth factors and opportunities
      • 9.2.7.2.2. Market size and forecast, by Disease Type
      • 9.2.7.2.3. Market size and forecast, by Treatment Type
      • 9.2.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.2.5. Market size and forecast, by Route of Administration
      • 9.2.7.2.6. Market size and forecast, by Distribution Channel
      • 9.2.7.3. Mexico
      • 9.2.7.3.1. Key market trends, growth factors and opportunities
      • 9.2.7.3.2. Market size and forecast, by Disease Type
      • 9.2.7.3.3. Market size and forecast, by Treatment Type
      • 9.2.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.2.7.3.5. Market size and forecast, by Route of Administration
      • 9.2.7.3.6. Market size and forecast, by Distribution Channel
  • 9.3. Europe
    • 9.3.1. Key trends and opportunities
    • 9.3.2. Market size and forecast, by Disease Type
    • 9.3.3. Market size and forecast, by Treatment Type
    • 9.3.4. Market size and forecast, by Drug Class Outlook
    • 9.3.5. Market size and forecast, by Route of Administration
    • 9.3.6. Market size and forecast, by Distribution Channel
    • 9.3.7. Market size and forecast, by country
      • 9.3.7.1. Germany
      • 9.3.7.1.1. Key market trends, growth factors and opportunities
      • 9.3.7.1.2. Market size and forecast, by Disease Type
      • 9.3.7.1.3. Market size and forecast, by Treatment Type
      • 9.3.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.1.5. Market size and forecast, by Route of Administration
      • 9.3.7.1.6. Market size and forecast, by Distribution Channel
      • 9.3.7.2. UK
      • 9.3.7.2.1. Key market trends, growth factors and opportunities
      • 9.3.7.2.2. Market size and forecast, by Disease Type
      • 9.3.7.2.3. Market size and forecast, by Treatment Type
      • 9.3.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.2.5. Market size and forecast, by Route of Administration
      • 9.3.7.2.6. Market size and forecast, by Distribution Channel
      • 9.3.7.3. France
      • 9.3.7.3.1. Key market trends, growth factors and opportunities
      • 9.3.7.3.2. Market size and forecast, by Disease Type
      • 9.3.7.3.3. Market size and forecast, by Treatment Type
      • 9.3.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.3.5. Market size and forecast, by Route of Administration
      • 9.3.7.3.6. Market size and forecast, by Distribution Channel
      • 9.3.7.4. Spain
      • 9.3.7.4.1. Key market trends, growth factors and opportunities
      • 9.3.7.4.2. Market size and forecast, by Disease Type
      • 9.3.7.4.3. Market size and forecast, by Treatment Type
      • 9.3.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.4.5. Market size and forecast, by Route of Administration
      • 9.3.7.4.6. Market size and forecast, by Distribution Channel
      • 9.3.7.5. Italy
      • 9.3.7.5.1. Key market trends, growth factors and opportunities
      • 9.3.7.5.2. Market size and forecast, by Disease Type
      • 9.3.7.5.3. Market size and forecast, by Treatment Type
      • 9.3.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.5.5. Market size and forecast, by Route of Administration
      • 9.3.7.5.6. Market size and forecast, by Distribution Channel
      • 9.3.7.6. Rest of Europe
      • 9.3.7.6.1. Key market trends, growth factors and opportunities
      • 9.3.7.6.2. Market size and forecast, by Disease Type
      • 9.3.7.6.3. Market size and forecast, by Treatment Type
      • 9.3.7.6.4. Market size and forecast, by Drug Class Outlook
      • 9.3.7.6.5. Market size and forecast, by Route of Administration
      • 9.3.7.6.6. Market size and forecast, by Distribution Channel
  • 9.4. Asia-Pacific
    • 9.4.1. Key trends and opportunities
    • 9.4.2. Market size and forecast, by Disease Type
    • 9.4.3. Market size and forecast, by Treatment Type
    • 9.4.4. Market size and forecast, by Drug Class Outlook
    • 9.4.5. Market size and forecast, by Route of Administration
    • 9.4.6. Market size and forecast, by Distribution Channel
    • 9.4.7. Market size and forecast, by country
      • 9.4.7.1. China
      • 9.4.7.1.1. Key market trends, growth factors and opportunities
      • 9.4.7.1.2. Market size and forecast, by Disease Type
      • 9.4.7.1.3. Market size and forecast, by Treatment Type
      • 9.4.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.1.5. Market size and forecast, by Route of Administration
      • 9.4.7.1.6. Market size and forecast, by Distribution Channel
      • 9.4.7.2. Japan
      • 9.4.7.2.1. Key market trends, growth factors and opportunities
      • 9.4.7.2.2. Market size and forecast, by Disease Type
      • 9.4.7.2.3. Market size and forecast, by Treatment Type
      • 9.4.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.2.5. Market size and forecast, by Route of Administration
      • 9.4.7.2.6. Market size and forecast, by Distribution Channel
      • 9.4.7.3. India
      • 9.4.7.3.1. Key market trends, growth factors and opportunities
      • 9.4.7.3.2. Market size and forecast, by Disease Type
      • 9.4.7.3.3. Market size and forecast, by Treatment Type
      • 9.4.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.3.5. Market size and forecast, by Route of Administration
      • 9.4.7.3.6. Market size and forecast, by Distribution Channel
      • 9.4.7.4. South Korea
      • 9.4.7.4.1. Key market trends, growth factors and opportunities
      • 9.4.7.4.2. Market size and forecast, by Disease Type
      • 9.4.7.4.3. Market size and forecast, by Treatment Type
      • 9.4.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.4.5. Market size and forecast, by Route of Administration
      • 9.4.7.4.6. Market size and forecast, by Distribution Channel
      • 9.4.7.5. Australia
      • 9.4.7.5.1. Key market trends, growth factors and opportunities
      • 9.4.7.5.2. Market size and forecast, by Disease Type
      • 9.4.7.5.3. Market size and forecast, by Treatment Type
      • 9.4.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.5.5. Market size and forecast, by Route of Administration
      • 9.4.7.5.6. Market size and forecast, by Distribution Channel
      • 9.4.7.6. Rest of Asia-Pacific
      • 9.4.7.6.1. Key market trends, growth factors and opportunities
      • 9.4.7.6.2. Market size and forecast, by Disease Type
      • 9.4.7.6.3. Market size and forecast, by Treatment Type
      • 9.4.7.6.4. Market size and forecast, by Drug Class Outlook
      • 9.4.7.6.5. Market size and forecast, by Route of Administration
      • 9.4.7.6.6. Market size and forecast, by Distribution Channel
  • 9.5. LAMEA
    • 9.5.1. Key trends and opportunities
    • 9.5.2. Market size and forecast, by Disease Type
    • 9.5.3. Market size and forecast, by Treatment Type
    • 9.5.4. Market size and forecast, by Drug Class Outlook
    • 9.5.5. Market size and forecast, by Route of Administration
    • 9.5.6. Market size and forecast, by Distribution Channel
    • 9.5.7. Market size and forecast, by country
      • 9.5.7.1. Brazil
      • 9.5.7.1.1. Key market trends, growth factors and opportunities
      • 9.5.7.1.2. Market size and forecast, by Disease Type
      • 9.5.7.1.3. Market size and forecast, by Treatment Type
      • 9.5.7.1.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.1.5. Market size and forecast, by Route of Administration
      • 9.5.7.1.6. Market size and forecast, by Distribution Channel
      • 9.5.7.2. United Arab Emirates
      • 9.5.7.2.1. Key market trends, growth factors and opportunities
      • 9.5.7.2.2. Market size and forecast, by Disease Type
      • 9.5.7.2.3. Market size and forecast, by Treatment Type
      • 9.5.7.2.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.2.5. Market size and forecast, by Route of Administration
      • 9.5.7.2.6. Market size and forecast, by Distribution Channel
      • 9.5.7.3. Saudi Arabia
      • 9.5.7.3.1. Key market trends, growth factors and opportunities
      • 9.5.7.3.2. Market size and forecast, by Disease Type
      • 9.5.7.3.3. Market size and forecast, by Treatment Type
      • 9.5.7.3.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.3.5. Market size and forecast, by Route of Administration
      • 9.5.7.3.6. Market size and forecast, by Distribution Channel
      • 9.5.7.4. South Africa
      • 9.5.7.4.1. Key market trends, growth factors and opportunities
      • 9.5.7.4.2. Market size and forecast, by Disease Type
      • 9.5.7.4.3. Market size and forecast, by Treatment Type
      • 9.5.7.4.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.4.5. Market size and forecast, by Route of Administration
      • 9.5.7.4.6. Market size and forecast, by Distribution Channel
      • 9.5.7.5. Rest of LAMEA
      • 9.5.7.5.1. Key market trends, growth factors and opportunities
      • 9.5.7.5.2. Market size and forecast, by Disease Type
      • 9.5.7.5.3. Market size and forecast, by Treatment Type
      • 9.5.7.5.4. Market size and forecast, by Drug Class Outlook
      • 9.5.7.5.5. Market size and forecast, by Route of Administration
      • 9.5.7.5.6. Market size and forecast, by Distribution Channel

CHAPTER 10: COMPETITIVE LANDSCAPE

  • 10.1. Introduction
  • 10.2. Top winning strategies
  • 10.3. Product Mapping of Top 10 Player
  • 10.4. Competitive Dashboard
  • 10.5. Competitive Heatmap
  • 10.6. Top player positioning, 2021

CHAPTER 11: COMPANY PROFILES

  • 11.1. Novartis AG
    • 11.1.1. Company overview
    • 11.1.2. Key Executives
    • 11.1.3. Company snapshot
  • 11.2. Pfizer, Inc.
    • 11.2.1. Company overview
    • 11.2.2. Key Executives
    • 11.2.3. Company snapshot
  • 11.3. Mylan N.V.
    • 11.3.1. Company overview
    • 11.3.2. Key Executives
    • 11.3.3. Company snapshot
  • 11.4. F. Hoffmann La Roche Ltd.
    • 11.4.1. Company overview
    • 11.4.2. Key Executives
    • 11.4.3. Company snapshot
  • 11.5. Eli Lilly And Company
    • 11.5.1. Company overview
    • 11.5.2. Key Executives
    • 11.5.3. Company snapshot
  • 11.6. Merck & Co., Inc.
    • 11.6.1. Company overview
    • 11.6.2. Key Executives
    • 11.6.3. Company snapshot
  • 11.7. Teva Pharmaceutical Industries Ltd.
    • 11.7.1. Company overview
    • 11.7.2. Key Executives
    • 11.7.3. Company snapshot
  • 11.8. Celltrion Healthcare Co., Ltd.
    • 11.8.1. Company overview
    • 11.8.2. Key Executives
    • 11.8.3. Company snapshot
  • 11.9. samsung bioepis
    • 11.9.1. Company overview
    • 11.9.2. Key Executives
    • 11.9.3. Company snapshot
  • 11.10. Bristol Myers Squibb Company
    • 11.10.1. Company overview
    • 11.10.2. Key Executives
    • 11.10.3. Company snapshot